Industry News
Biotechnology Industry News
Sanofi’s TSLP and IL-13…
Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 eczema trial.
The agreement allows Biogen to…
The agreement allows Biogen to apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for milestone payments and tiered royalties on any resulting products.
Takeda has terminated a neuro…
Takeda has terminated a neuro partnership with Denali Therapeutics as the Japanese pharma undergoes a massive restructuring marked by significant layoffs.
AI powerhouse Anthropic is…
AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric
After securing a…
After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug discovery company Syneron Bio has announced the closing of a $150 million series B round to support its
The number of drugs in development…
The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. While methodological changes may have affected the result, the dip highlights a period when drugmakers
After a career-long tenure at…
After a career-long tenure at Bayer, Nelson Ambrogio has climbed the ranks to the top of the pharma heap as newly appointed president of the German conglomerate’s U.S. pharmaceuticals division. The executive will officially take
Ferring Pharmaceuticals is halting…
Ferring Pharmaceuticals is halting work on two trials of a phase 1 infertility candidate that together had enrolled 416 patients.
Immunovant’s first-generation…
Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of commercializing the drug.
Alto Neurosciences is halting work…
Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study.
After the FDA placed two of its…
After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the affected trials.
Stipple Bio is connecting the dots…
Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision oncology asset as it emerges from stealth with a $100 million series A financing round.
After emerging from stealth last…
After emerging from stealth last month with $175 million in funding, Korsana Biosciences has wasted no time making its way to the public markets.
Oric Pharmaceuticals has picked…
Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while outlining a claimed edge over Pfizer’s rival candidate.
Have we passed the peak of biotech…
Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures.
ctDNA assays are changing how…
ctDNA assays are changing how hematologic cancers are monitored, from MRD detection to clinical trial design.
Half a year after being spurned by…
Half a year after being spurned by the FDA and following several rounds of deep layoffs, IO Biotech has decided to close its doors for good.
Ambrosia Biosciences is aiming to…
Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million series B round.
Eli Lilly has gone big in the name…
Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals and its sleep disorder pipeline.
A phase 3 trial of AstraZeneca’s…
A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the company’s ability to expand beyond the children served by its existing drug.